Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1

Interventions

Cisplatin 7pembrolizumab 4Radiotherapy 3Paclitaxel 3fludarabine 2durvalumab 2aldesleukin 2Taxes 2Fluorouracil 2Cyclophosphamide 2Biopsy 2veliparib 1tremelimumab 1prednylidene 1niraparib 1fludarabine phosphate 1exifone 1entinostat 1dostarlimab 1deltacortene 1dehydroftorafur 1bintrafusp alfa protein, human 1advexin 1Tomography, X-Ray Computed 1Specimen Handling 1Radiosurgery 1Radiation 1Prednisone 1Platinum 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oropharyngeal Neoplasms × Hydroxyurea × Clear all
NCT01711541 2023-06-07

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
24 enrolled 12 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡